Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05858619 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Molecular Signatures of Cutaneous Dupilumab Response

Name: Molecular Signatures of Cutaneous Dupilumab Response — clinical trial record (NCT05858619)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 4

SponsorUniversity of California, San Francisco

Started2023-02-01

View on ClinicalTrials.gov ↗

Amendment history

2026-06-01

Study Status v2

Primary completion date2026-02-01→2028-02-01

Completion date2026-02-01→2028-02-01

2024-06-25

Study Status, Arms and Interventions v1

Re-verified, no change to tracked fields

2023-05-04

Original filing

University of California, San Francisco

637 trials monitored

See 53 trials at risk

Atopic Dermatitis

489 trials monitored

See 14 trials at risk

This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.

Trial Details

NCT Number	NCT05858619
Lead Sponsor	University of California, San Francisco
Conditions	Atopic Dermatitis
Enrollment	15 participants
Start Date	2023-02-01
Primary Completion	2028-02-01 (estimated)
Study Completion	2028-02-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-04